Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review.
Immunotherapy
Radiosurgery
Safety
Systemic therapy
Targeted therapy
Toxicity
Journal
Cancer metastasis reviews
ISSN: 1573-7233
Titre abrégé: Cancer Metastasis Rev
Pays: Netherlands
ID NLM: 8605731
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
13
11
2020
accepted:
15
12
2020
pubmed:
5
1
2021
medline:
26
11
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
Stereotactic radiosurgery (SRS) is a standard option for brain metastases (BM). There is lack of consensus when patients have a systemic treatment, if a washout is necessary. The aim of this review is to analyze the toxicity of SRS when it is concurrent with chemotherapies, immunotherapy, and/or targeted therapies. From Medline and Embase databases, we searched for English literature published up to April 2020 according to the PRISMA guidelines, using for key words the list of the main systemic therapies currently in use And "radiosurgery," "SRS," "GKRS," "Gamma Knife," "toxicity," "ARE," "radiation necrosis," "safety," "brain metastases." Studies reporting safety or toxicity with SRS concurrent with systemic treatment for BM were included. Of 852 abstracts recorded, 77 were included. The main cancers were melanoma, lung, breast, and renal carcinoma. These studies cumulate 6384 patients. The median SRS dose prescription was 20 Gy [12-30] .For some, they compared a concurrent arm with a non-concurrent or a SRS-alone arm. There were no skin toxicities, no clearly increased rate of bleeding, or radiation necrosis with significant clinical impact. SRS combined with systemic therapy appears to be safe, allowing the continuation of treatment when brain SRS is considered.
Identifiants
pubmed: 33392851
doi: 10.1007/s10555-020-09949-9
pii: 10.1007/s10555-020-09949-9
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-354Références
Yamamoto, M., Higuchi, Y., Sato, Y., Aiyama, H., Kasuya, H., & Barfod, B. E. (2019). Stereotactic radiosurgery for patients with 10 or more brain metastases. In A. Niranjan, L. D. Lunsford, & H. Kano (Eds.), Progress in neurological surgery (Vol. 34, pp. 110–124). S. Karger AG. https://doi.org/10.1159/000493056 .
Tallet, A. V., Dhermain, F., Le Rhun, E., Noël, G., & Kirova, Y. M. (2017). Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. Annals of Oncology, 28(12), 2962–2976. https://doi.org/10.1093/annonc/mdx408 .
doi: 10.1093/annonc/mdx408
pubmed: 29045524
Anker, C. J., Grossmann, K. F., Atkins, M. B., Suneja, G., Tarhini, A. A., & Kirkwood, J. M. (2016). Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). International Journal of Radiation Oncology, Biology, Physics, 95(2), 632–646. https://doi.org/10.1016/j.ijrobp.2016.01.038 .
doi: 10.1016/j.ijrobp.2016.01.038
pubmed: 27131079
pmcid: 5102246
Verduin, M., Zindler, J. D., Martinussen, H. M. A., Jansen, R. L. H., Croes, S., Hendriks, L. E. L., Eekers, D. B. P., & Hoeben, A. (2017). Use of systemic therapy concurrent with cranial radiotherapy for cerebral metastases of solid tumors. Oncologist, 22(2), 222–235. https://doi.org/10.1634/theoncologist.2016-0117 .
doi: 10.1634/theoncologist.2016-0117
pubmed: 28167569
pmcid: 5330699
Levy, A., Faivre-Finn, C., Hasan, B., De Maio, E., Berghoff, A. S., Girard, N., et al. (2018). Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. European Journal of Cancer, 93, 37–46. https://doi.org/10.1016/j.ejca.2018.01.067 .
doi: 10.1016/j.ejca.2018.01.067
pubmed: 29477100
Addeo, R., Caraglia, M., Faiola, V., Capasso, E., Vincenzi, B., Montella, L., et al. (2007). Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer, 7(1), 18. https://doi.org/10.1186/1471-2407-7-18 .
doi: 10.1186/1471-2407-7-18
pubmed: 17254350
pmcid: 1794253
Cao, K. I., Lebas, N., Gerber, S., Levy, C., Le Scodan, R., Bourgier, C., et al. (2015). Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Annals of Oncology, 26(1), 89–94. https://doi.org/10.1093/annonc/mdu488 .
doi: 10.1093/annonc/mdu488
pubmed: 25355723
Cagney, D. N., Martin, A. M., Catalano, P. J., Reitman, Z. J., Mezochow, G. A., Lee, E. Q., Wen, P. Y., Weiss, S. E., Brown, P. D., Ahluwalia, M. S., Arvold, N. D., Tanguturi, S. K., Haas-Kogan, D. A., Alexander, B. M., Redig, A. J., & Aizer, A. A. (2018). Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 126(3), 511–518. https://doi.org/10.1016/j.radonc.2018.01.005 .
doi: 10.1016/j.radonc.2018.01.005
pubmed: 29398153
Morris, S.-A. L., Zhu, P., Rao, M., Martir, M., Zhu, J. J., Hsu, S., Ballester, L. Y., Day, A. L., Tandon, N., Kim, D. H., Shepard, S., Blanco, A., & Esquenazi, Y. (2019). Gamma knife stereotactic radiosurgery in combination with bevacizumab for recurrent glioblastoma. World Neurosurgery, 127, e523–e533. https://doi.org/10.1016/j.wneu.2019.03.193 .
doi: 10.1016/j.wneu.2019.03.193
pubmed: 30954746
Cuneo, K. C., Vredenburgh, J. J., Sampson, J. H., Reardon, D. A., Desjardins, A., Peters, K. B., Friedman, H. S., Willett, C. G., & Kirkpatrick, J. P. (2012). Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics, 82(5), 2018–2024. https://doi.org/10.1016/j.ijrobp.2010.12.074 .
doi: 10.1016/j.ijrobp.2010.12.074
pubmed: 21489708
Wang, Y., Wang, E., Pan, L., Dai, J., Zhang, N., Wang, X., Liu, X., Mei, G., & Sheng, X. (2014). A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. Journal of Neuro-Oncology, 119(2), 369–376. https://doi.org/10.1007/s11060-014-1488-0 .
doi: 10.1007/s11060-014-1488-0
pubmed: 24879376
Yomo, S., & Hayashi, M. (2016). Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report. Journal of Neuro-Oncology, 127(1), 119–126. https://doi.org/10.1007/s11060-015-2019-3 .
doi: 10.1007/s11060-015-2019-3
pubmed: 26619997
Guinde, J., Carron, R., Tomasini, P., Greillier, L., Régis, J., & Barlesi, F. (2017). Bevacizumab plus radiosurgery for nonsquamous non–small cell lung cancer patients with brain metastases: safe combination? World Neurosurgery, 107, 1047.e1–1047.e4. https://doi.org/10.1016/j.wneu.2017.07.185 .
doi: 10.1016/j.wneu.2017.07.185
Staehler, M., Haseke, N., Nuhn, P., Tüllmann, C., Karl, A., Siebels, M., Stief, C. G., Wowra, B., & Muacevic, A. (2011). Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma: anti-angiogenic therapy and radiosurgery in metastatic RCC. BJU International, no-no. https://doi.org/10.1111/j.1464-410X.2010.09895.x .
Juloori, A., Miller, J. A., Parsai, S., Kotecha, R., Ahluwalia, M. S., Mohammadi, A. M., Murphy, E. S., Suh, J. H., Barnett, G. H., Yu, J. S., Vogelbaum, M. A., Rini, B., Garcia, J., Stevens, G. H., Angelov, L., & Chao, S. T. (2020). Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. Journal of Neurosurgery, 132(1), 188–196. https://doi.org/10.3171/2018.8.JNS182100 .
doi: 10.3171/2018.8.JNS182100
Ahluwalia, M. S., Chao, S. T., Parsons, M. W., Suh, J. H., Wang, D., Mikkelsen, T., Brewer, C. J., Smolenski, K. N., Schilero, C., Rump, M., Elson, P., Angelov, L., Barnett, G. H., Vogelbaum, M. A., Weil, R. J., & Peereboom, D. M. (2015). Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases. Journal of Neuro-Oncology, 124(3), 485–491. https://doi.org/10.1007/s11060-015-1862-6 .
doi: 10.1007/s11060-015-1862-6
pubmed: 26245136
Arneson, K., Mondschein, J., Stavas, M., Cmelak, A. J., Attia, A., Horn, L., Niermann, K., Puzanov, I., Chakravarthy, A. B., & Xia, F. (2017). A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of Neuro-Oncology, 133(2), 435–442. https://doi.org/10.1007/s11060-017-2455-3 .
doi: 10.1007/s11060-017-2455-3
pubmed: 28488066
Schwer, A. L., Damek, D. M., Kavanagh, B. D., Gaspar, L. E., Lillehei, K., Stuhr, K., & Chen, C. (2008). A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics, 70(4), 993–1001. https://doi.org/10.1016/j.ijrobp.2007.07.2382 .
doi: 10.1016/j.ijrobp.2007.07.2382
pubmed: 17967517
Kim, H. J., Kim, W. S., Kwon, D. H., Cho, Y. H., & Choi, C.-M. (2015). Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung Cancer. Journal of Korean Neurosurgical Society, 58(3), 205. https://doi.org/10.3340/jkns.2015.58.3.205 .
doi: 10.3340/jkns.2015.58.3.205
pubmed: 26539262
pmcid: 4630350
Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., Souhami, L., Buyyounouski, M. K., Khuntia, D., Demas, W., Shah, S. A., Nedzi, L. A., Perry, G., Suh, J. H., & Mehta, M. P. (2013). A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. International Journal of Radiation Oncology, Biology, Physics, 85(5), 1312–1318. https://doi.org/10.1016/j.ijrobp.2012.11.042 .
doi: 10.1016/j.ijrobp.2012.11.042
pubmed: 23391814
pmcid: 3740376
Yomo, S., Serizawa, T., Yamamoto, M., Higuchi, Y., Sato, Y., Shuto, T., Akabane, A., Jokura, H., Kawagishi, J., & Aoyama, H. (2019). The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after gamma knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI). Journal of Neuro-Oncology, 145(1), 151–157. https://doi.org/10.1007/s11060-019-03282-0 .
doi: 10.1007/s11060-019-03282-0
pubmed: 31487030
Zhuang, H., Tao, L., Wang, X., Shi, S., Yuan, Z., Wang, E., & Chang, J. Y. (2020). Tyrosine kinase inhibitor resistance increased the risk of cerebral radiation necrosis after stereotactic radiosurgery in brain metastases of non-small-cell lung cancer: a multi-institutional retrospective case-control study. Frontiers in Oncology, 10, 12. https://doi.org/10.3389/fonc.2020.00012 .
doi: 10.3389/fonc.2020.00012
pubmed: 32117704
pmcid: 7026471
Yomo, S., Hayashi, M., & Cho, N. (2013). Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. Journal of Neuro-Oncology, 112(2), 199–207. https://doi.org/10.1007/s11060-013-1046-1 .
doi: 10.1007/s11060-013-1046-1
pubmed: 23296546
Kim, J. M., Miller, J. A., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Peereboom, D. M., Mohammadi, A. M., Barnett, G. H., Murphy, E. S., Vogelbaum, M. A., Angelov, L., Abraham, J., Moore, H., Budd, G. T., & Suh, J. H. (2019). Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro-Oncology, 21(5), 659–668. https://doi.org/10.1093/neuonc/noz006 .
doi: 10.1093/neuonc/noz006
pubmed: 30726965
pmcid: 6502492
Parsai, S., Miller, J. A., Juloori, A., Chao, S. T., Kotecha, R., Mohammadi, A. M., Ahluwalia, M. S., Murphy, E. S., Barnett, G. H., Vogelbaum, M. A., Angelov, L., Peereboom, D. M., & Suh, J. H. (2020). Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. Journal of Neurosurgery, 132(2), 503–511. https://doi.org/10.3171/2018.10.JNS182340 .
doi: 10.3171/2018.10.JNS182340
Fan, Y., Xu, Y., Gong, L., Fang, L., Lu, H., Qin, J., et al. (2017). Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Scientific Reports, 7(1), 45193. https://doi.org/10.1038/srep45193 .
doi: 10.1038/srep45193
pubmed: 28332624
pmcid: 5362911
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR -mutant lung cancer with brain metastases: results from a single-center retrospective study. Oncologist, 24(6), 836–843. https://doi.org/10.1634/theoncologist.2018-0264 .
doi: 10.1634/theoncologist.2018-0264
pubmed: 30126856
Armstrong, K., Ward, J., Dunne, M., Rock, L., Westrup, J., Mascott, C. R., Thirion, P., & Mihai, A. M. (2019). Linac-based radiosurgery for patients with brain oligometastases from a breast primary, in the trastuzumab era-impact of tumor phenotype and prescribed SRS dose. Frontiers in Oncology, 9, 377. https://doi.org/10.3389/fonc.2019.00377 .
doi: 10.3389/fonc.2019.00377
pubmed: 31192116
pmcid: 6547789
Geraud, A., Xu, H. P., Beuzeboc, P., & Kirova, Y. M. (2017). Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. Journal of Neuro-Oncology, 131(1), 69–72. https://doi.org/10.1007/s11060-016-2265-z .
doi: 10.1007/s11060-016-2265-z
pubmed: 27995546
Stumpf, P. K., Cittelly, D. M., Robin, T. P., Carlson, J. A., Stuhr, K. A., Contreras-Zarate, M. J., Lai, S., Ormond, D. R., Rusthoven, C. G., Gaspar, L. E., Rabinovitch, R., Kavanagh, B. D., Liu, A., Diamond, J. R., Kabos, P., & Fisher, C. M. (2019). Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4. Clinical Cancer Research, 25(13), 3946–3953. https://doi.org/10.1158/1078-0432.CCR-18-2851 .
doi: 10.1158/1078-0432.CCR-18-2851
pubmed: 30940654
pmcid: 6751332
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Müller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V., & Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26(6), 1238–1244. https://doi.org/10.1093/annonc/mdv139 .
doi: 10.1093/annonc/mdv139
pubmed: 25762352
Rompoti, N., Schilling, B., Livingstone, E., Griewank, K., Hillen, U., Sauerwein, W., Pöttgen, C., Stuschke, M., Schadendorf, D., & Zimmer, L. (2013). Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. Journal of Clinical Oncology, 31(30), 3844–3845. https://doi.org/10.1200/JCO.2013.50.8473 .
doi: 10.1200/JCO.2013.50.8473
pubmed: 24062392
Peuvrel, L., Ruellan, A.-L., Thillays, F., Quereux, G., Brocard, A., Saint-Jean, M., Aumont, M., Drouet, F., & Dreno, B. (2013). Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. European Journal of Dermatology, 23(6), 879–881. https://doi.org/10.1684/ejd.2013.2193 .
doi: 10.1684/ejd.2013.2193
pubmed: 24192487
Gaudy-Marqueste, C., Carron, R., Delsanti, C., Loundou, A., Monestier, S., Archier, E., Richard, M. A., Regis, J., & Grob, J. J. (2014). On demand gamma-knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Annals of Oncology, 25(10), 2086–2091. https://doi.org/10.1093/annonc/mdu266 .
doi: 10.1093/annonc/mdu266
pubmed: 25057167
Xu, Z., Lee, C.-C., Ramesh, A., Mueller, A. C., Schlesinger, D., Cohen-Inbar, O., Shih, H. H., & Sheehan, J. P. (2017). BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. Journal of Neurosurgery, 126(3), 726–734. https://doi.org/10.3171/2016.2.JNS1633 .
doi: 10.3171/2016.2.JNS1633
pubmed: 27203149
Ahmed, K. A., Freilich, J. M., Sloot, S., Figura, N., Gibney, G. T., Weber, J. S., Sarangkasiri, S., Chinnaiyan, P., Forsyth, P. A., Etame, A. B., & Rao, N. G. (2015). LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. Journal of Neuro-Oncology, 122(1), 121–126. https://doi.org/10.1007/s11060-014-1685-x .
doi: 10.1007/s11060-014-1685-x
pubmed: 25519302
Acharya, S., Mahmood, M., Mullen, D., Yang, D., Tsien, C. I., Huang, J., Perkins, S. M., Rich, K., Chicoine, M., Leuthardt, E., Dowling, J., Dunn, G., Keller, J., Robinson, C. G., & Abraham, C. (2017). Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. Advances in Radiation Oncology, 2(4), 572–580. https://doi.org/10.1016/j.adro.2017.07.003 .
doi: 10.1016/j.adro.2017.07.003
pubmed: 29204524
pmcid: 5707419
Ly, D., Bagshaw, H. P., Anker, C. J., Tward, J. D., Grossmann, K. F., Jensen, R. L., & Shrieve, D. C. (2015). Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. Journal of Neurosurgery, 123(2), 395–401. https://doi.org/10.3171/2014.9.JNS141425 .
doi: 10.3171/2014.9.JNS141425
pubmed: 25768829
Patel, K. R., Chowdhary, M., Switchenko, J. M., Kudchadkar, R., Lawson, D. H., Cassidy, R. J., Prabhu, R. S., & Khan, M. K. (2016). BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Research, 26(4), 387–394. https://doi.org/10.1097/CMR.0000000000000268 .
doi: 10.1097/CMR.0000000000000268
pubmed: 27223498
pmcid: 4943024
Mastorakos, P., Xu, Z., Yu, J., Hess, J., Qian, J., Chatrath, A., Taylor, D. G., Kondziolka, D., Warnick, R., Chiang, V., & Sheehan, J. (2019). BRAF V600 mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study. Neurosurgery, 84(4), 868–880. https://doi.org/10.1093/neuros/nyy203 .
doi: 10.1093/neuros/nyy203
pubmed: 29846702
Wolf, A., Zia, S., Verma, R., Pavlick, A., Wilson, M., Golfinos, J. G., Silverman, J. S., & Kondziolka, D. (2016). Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. Journal of Neuro-Oncology, 127(3), 607–615. https://doi.org/10.1007/s11060-016-2072-6 .
doi: 10.1007/s11060-016-2072-6
pubmed: 26852222
Choi, J. W., Kong, D.-S., Seol, H. J., Nam, D.-H., Yoo, K. H., Sun, J.-M., Ahn, J. S., Ahn, M. J., Park, K., & Lee, J.-I. (2016). Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non–small cell lung cancer. World Neurosurgery, 95, 399–405. https://doi.org/10.1016/j.wneu.2016.08.046 .
doi: 10.1016/j.wneu.2016.08.046
pubmed: 27565474
Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A., Lovly, C. M., Goldberg, S., Beal, K., Yu, J. B., Kavanagh, B. D., Chiang, V. L., Camidge, D. R., & Contessa, J. N. (2016). Extended survival and prognostic factors for patients with ALK -rearranged non–small-cell lung cancer and brain metastasis. Journal of Clinical Oncology, 34(2), 123–129. https://doi.org/10.1200/JCO.2015.62.0138 .
doi: 10.1200/JCO.2015.62.0138
pubmed: 26438117
Figura, N. B., Potluri, T. K., Mohammadi, H., Oliver, D. E., Arrington, J. A., Robinson, T. J., Etame, A. B., Tran, N. D., Liu, J. K., Soliman, H., Forsyth, P. A., Sahebjam, S., Yu, H. M., Han, H. S., & Ahmed, K. A. (2019). CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. Journal of Neuro-Oncology, 144(3), 583–589. https://doi.org/10.1007/s11060-019-03260-6 .
doi: 10.1007/s11060-019-03260-6
pubmed: 31399935
Patel, B. G., Ahmed, K. A., Johnstone, P. A. S., Yu, H.-H. M., & Etame, A. B. (2016). Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Research, 26(4), 382–386. https://doi.org/10.1097/CMR.0000000000000250 .
doi: 10.1097/CMR.0000000000000250
pubmed: 26926151
Choong, E. S., Lo, S., Drummond, M., Fogarty, G. B., Menzies, A. M., Guminski, A., Shivalingam, B., Clarke, K., Long, G. V., & Hong, A. M. (2017). Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 75, 169–178. https://doi.org/10.1016/j.ejca.2017.01.007 .
doi: 10.1016/j.ejca.2017.01.007
pubmed: 28236768
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019). Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiotherapy and Oncology, 130, 104–112. https://doi.org/10.1016/j.radonc.2018.08.025 .
doi: 10.1016/j.radonc.2018.08.025
pubmed: 30241791
Cohen-Inbar, O., Shih, H.-H., Xu, Z., Schlesinger, D., & Sheehan, J. P. (2017). The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. Journal of Neurosurgery, 127(5), 1007–1014. https://doi.org/10.3171/2016.9.JNS161585 .
doi: 10.3171/2016.9.JNS161585
pubmed: 28059663
Diao, K., Bian, S. X., Routman, D. M., Yu, C., Ye, J. C., Wagle, N. A., Wong, M. K., Zada, G., & Chang, E. L. (2018). Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. Journal of Neuro-Oncology, 139(2), 421–429. https://doi.org/10.1007/s11060-018-2880-y .
doi: 10.1007/s11060-018-2880-y
pubmed: 29696531
pmcid: 7469981
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015). Stereotactic radiosurgery for melanoma brain metastases in patients receiving Ipilimumab: safety profile and efficacy of combined treatment. International Journal of Radiation Oncology, Biology, Physics, 92(2), 368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004 .
doi: 10.1016/j.ijrobp.2015.01.004
pubmed: 25754629
pmcid: 4955924
Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013). Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Research, 23(3), 191–195. https://doi.org/10.1097/CMR.0b013e32835f3d90 .
doi: 10.1097/CMR.0b013e32835f3d90
pubmed: 23462208
Olson, A. C., Thomas, S., Qin, R., Singh, B., Salama, J. K., Kirkpatrick, J., & Salama, A. K. (2016). Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. Melanoma Management, 3(3), 177–186. https://doi.org/10.2217/mmt-2016-0004 .
doi: 10.2217/mmt-2016-0004
pubmed: 30190887
pmcid: 6094592
Patel, K. R., Shoukat, S., Oliver, D. E., Chowdhary, M., Rizzo, M., Lawson, D. H., Khosa, F., Liu, Y., & Khan, M. K. (2017). Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. American Journal of Clinical Oncology, 40(5), 444–450. https://doi.org/10.1097/COC.0000000000000199 .
doi: 10.1097/COC.0000000000000199
pubmed: 26017484
Skrepnik, T., Sundararajan, S., Cui, H., & Stea, B. (2017). Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. OncoImmunology, 6(3), e1283461. https://doi.org/10.1080/2162402X.2017.1283461 .
doi: 10.1080/2162402X.2017.1283461
pubmed: 28405509
pmcid: 5384342
Tazi, K., Hathaway, A., Chiuzan, C., & Shirai, K. (2015). Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Medicine, 4(1), 1–6. https://doi.org/10.1002/cam4.315 .
doi: 10.1002/cam4.315
pubmed: 25164960
Williams, N. L., Wuthrick, E. J., Kim, H., Palmer, J. D., Garg, S., Eldredge-Hindy, H., Daskalakis, C., Feeney, K. J., Mastrangelo, M. J., Kim, L. J., Sato, T., Kendra, K. L., Olencki, T., Liebner, D. A., Farrell, C. J., Evans, J. J., Judy, K. D., Andrews, D. W., Dicker, A. P., Werner-Wasik, M., & Shi, W. (2017). Phase 1 study of Ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. International Journal of Radiation Oncology, Biology, Physics, 99(1), 22–30. https://doi.org/10.1016/j.ijrobp.2017.05.028 .
doi: 10.1016/j.ijrobp.2017.05.028
pubmed: 28816150
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H. H. M., Etame, A. B., Weber, J. S., & Gibney, G. T. (2016). Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of Oncology, 27(3), 434–441. https://doi.org/10.1093/annonc/mdv622 .
doi: 10.1093/annonc/mdv622
pubmed: 26712903
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A., Yamada, Y., & Beal, K. (2017). Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Journal for Immunotherapy of Cancer, 5(1), 76. https://doi.org/10.1186/s40425-017-0282-x .
doi: 10.1186/s40425-017-0282-x
pubmed: 29037215
pmcid: 5644249
Hubbeling, H. G., Schapira, E. F., Horick, N. K., Goodwin, K. E. H., Lin, J. J., Oh, K. S., Shaw, A. T., Mehan, W. A., Shih, H. A., & Gainor, J. F. (2018). Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non–small cell lung cancer. Journal of Thoracic Oncology, 13(4), 550–558. https://doi.org/10.1016/j.jtho.2018.01.012 .
doi: 10.1016/j.jtho.2018.01.012
pubmed: 29378267
Kotecha, R., Kim, J. M., Miller, J. A., Juloori, A., Chao, S. T., Murphy, E. S., Peereboom, D. M., Mohammadi, A. M., Barnett, G. H., Vogelbaum, M. A., Angelov, L., Suh, J. H., & Ahluwalia, M. S. (2019). The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology, 21(8), 1060–1068. https://doi.org/10.1093/neuonc/noz046 .
doi: 10.1093/neuonc/noz046
pubmed: 30796838
pmcid: 6682202
Nardin, C., Mateus, C., Texier, M., Lanoy, E., Hibat-Allah, S., Ammari, S., Robert, C., & Dhermain, F. (2018). Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Research, 28(2), 111–119. https://doi.org/10.1097/CMR.0000000000000413 .
doi: 10.1097/CMR.0000000000000413
pubmed: 29356789
Schapira, E., Hubbeling, H., Yeap, B. Y., Mehan, W. A., Shaw, A. T., Oh, K., et al. (2018). Improved overall survival and Locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. International Journal of Radiation Oncology, Biology, Physics, 101(3), 624–629. https://doi.org/10.1016/j.ijrobp.2018.02.175 .
doi: 10.1016/j.ijrobp.2018.02.175
pubmed: 29678530
Shepard, M. J., Xu, Z., Donahue, J., Eluvathingal Muttikkal, T. J., Cordeiro, D., Hansen, L., et al. (2019). Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study. Journal of Neurosurgery, 1–8. https://doi.org/10.3171/2019.4.JNS19822 .
Trommer-Nestler, M., Marnitz, S., Kocher, M., Rueß, D., Schlaak, M., Theurich, S., von Bergwelt-Baildon, M., Morgenthaler, J., Jablonska, K., Celik, E., Ruge, M., & Baues, C. (2018). Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment. International Journal of Molecular Sciences, 19(9), 2653. https://doi.org/10.3390/ijms19092653 .
doi: 10.3390/ijms19092653
pmcid: 6164579
Arscott, W. T., Zhu, S., Plastaras, J. P., Maity, A., Alonso-Basanta, M., & Jones, J. (2019). Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. Neuro-Oncology Practice, 6(4), 297–304. https://doi.org/10.1093/nop/npy042 .
doi: 10.1093/nop/npy042
pubmed: 31386046
Chen, L., Douglass, J., Kleinberg, L., Ye, X., Marciscano, A. E., Forde, P. M., Brahmer, J., Lipson, E., Sharfman, W., Hammers, H., Naidoo, J., Bettegowda, C., Lim, M., & Redmond, K. J. (2018). Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. International Journal of Radiation Oncology, Biology, Physics, 100(4), 916–925. https://doi.org/10.1016/j.ijrobp.2017.11.041 .
doi: 10.1016/j.ijrobp.2017.11.041
pubmed: 29485071
Minniti, G., Anzellini, D., Reverberi, C., Cappellini, G. C. A., Marchetti, L., Bianciardi, F., Bozzao, A., Osti, M., Gentile, P. C., & Esposito, V. (2019). Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. Journal for Immunotherapy of Cancer, 7(1), 102. https://doi.org/10.1186/s40425-019-0588-y .
doi: 10.1186/s40425-019-0588-y
pubmed: 30975225
pmcid: 6458744
Murphy, B., Walker, J., Bassale, S., Monaco, D., Jaboin, J., Ciporen, J., Taylor, M., & Dai Kubicky, C. (2019). Concurrent radiosurgery and immune checkpoint inhibition: improving regional intracranial control for patients with metastatic melanoma. American Journal of Clinical Oncology, 42(3), 253–257. https://doi.org/10.1097/COC.0000000000000509 .
doi: 10.1097/COC.0000000000000509
pubmed: 30557166
Qian, J. M., Yu, J. B., Kluger, H. M., & Chiang, V. L. S. (2016). Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery: immunotherapy and SRS in brain metastases. Cancer, 122(19), 3051–3058. https://doi.org/10.1002/cncr.30138 .
doi: 10.1002/cncr.30138
pubmed: 27285122
pmcid: 5030143
Rahman, R., Cortes, A., Niemierko, A., Oh, K. S., Flaherty, K. T., Lawrence, D. P., Sullivan, R. J., & Shih, H. A. (2018). The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. Journal of Neuro-Oncology, 138(2), 299–306. https://doi.org/10.1007/s11060-018-2795-7 .
doi: 10.1007/s11060-018-2795-7
pubmed: 29453679
Weingarten, N., Kruser, T. J., & Bloch, O. (2019). Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. Clinical Neurology and Neurosurgery, 179, 14–18. https://doi.org/10.1016/j.clineuro.2019.02.010 .
doi: 10.1016/j.clineuro.2019.02.010
pubmed: 30784894
Yusuf, M. B., Amsbaugh, M. J., Burton, E., Chesney, J., & Woo, S. (2017). Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: investigating efficacy and the effects of relative treatment timing on lesion response. World Neurosurgery, 100, 632–640.e4. https://doi.org/10.1016/j.wneu.2017.01.101 .
doi: 10.1016/j.wneu.2017.01.101
pubmed: 28179176
Colaco, R. J., Martin, P., Kluger, H. M., Yu, J. B., & Chiang, V. L. (2016). Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Journal of Neurosurgery, 125(1), 17–23. https://doi.org/10.3171/2015.6.JNS142763 .
doi: 10.3171/2015.6.JNS142763
pubmed: 26544782
Couty, E., Vallard, A., Sotton, S., Ouni, S., Garcia, M.-A., Espenel, S., Rancoule, C., Ben Mrad, M., Biron, A. C., Perrot, J. L., Langrand-Escure, J., & Magné, N. (2019). Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report: radiation/systemic drug combo in metastatic melanoma. Cancer Chemotherapy and Pharmacology, 83(5), 881–892. https://doi.org/10.1007/s00280-019-03806-5 .
doi: 10.1007/s00280-019-03806-5
pubmed: 30806760
Gatterbauer, B., Hirschmann, D., Eberherr, N., Untersteiner, H., Cho, A., Shaltout, A., Göbl, P., Fitschek, F., Dorfer, C., Wolfsberger, S., Kasprian, G., Höller, C., & Frischer, J. M. (2020). Toxicity and efficacy of gamma knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-a retrospective cohort study. Cancer Medicine, 9, 4026–4036. https://doi.org/10.1002/cam4.3021 .
doi: 10.1002/cam4.3021
pubmed: 32249551
pmcid: 7286469
Hadi, I., Roengvoraphoj, O., Bodensohn, R., Hofmaier, J., Niyazi, M., Belka, C., & Nachbichler, S. B. (2020). Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis. Radiation Oncology, 15(1), 37. https://doi.org/10.1186/s13014-020-1485-8 .
doi: 10.1186/s13014-020-1485-8
pubmed: 32059731
Kim, J. M., Miller, J. A., Kotecha, R., Xiao, R., Juloori, A., Ward, M. C., Ahluwalia, M. S., Mohammadi, A. M., Peereboom, D. M., Murphy, E. S., Suh, J. H., Barnett, G. H., Vogelbaum, M. A., Angelov, L., Stevens, G. H., & Chao, S. T. (2017). The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. Journal of Neuro-Oncology, 133(2), 357–368. https://doi.org/10.1007/s11060-017-2442-8 .
doi: 10.1007/s11060-017-2442-8
pubmed: 28434110
Klausner, G., Troussier, I., Biau, J., Jacob, J., Schernberg, A., Canova, C.-H., Simon, J. M., Borius, P. Y., Malouf, G., Spano, J. P., Roupret, M., Cornu, P., Mazeron, J. J., Valéry, C., Feuvret, L., & Maingon, P. (2019). Stereotactic radiation therapy for renal cell carcinoma brain metastases in the tyrosine kinase inhibitors era: outcomes of 120 patients. Clinical Genitourinary Cancer, 17(3), 191–200. https://doi.org/10.1016/j.clgc.2019.02.007 .
doi: 10.1016/j.clgc.2019.02.007
pubmed: 30926219
Kotecha, R., Miller, J. A., Venur, V. A., Mohammadi, A. M., Chao, S. T., Suh, J. H., Barnett, G. H., Murphy, E. S., Funchain, P., Yu, J. S., Vogelbaum, M. A., Angelov, L., & Ahluwalia, M. S. (2018). Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. Journal of Neurosurgery, 129(1), 50–59. https://doi.org/10.3171/2017.1.JNS162797 .
doi: 10.3171/2017.1.JNS162797
pubmed: 28799876
Miller, J. A., Kotecha, R., Ahluwalia, M. S., Mohammadi, A. M., Chao, S. T., Barnett, G. H., Murphy, E. S., Vogelbaum, M. A., Angelov, L., Peereboom, D. M., & Suh, J. H. (2017). Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies: breast cancer brain metastasis. Cancer, 123(12), 2283–2293. https://doi.org/10.1002/cncr.30616 .
doi: 10.1002/cncr.30616
pubmed: 28192598
Shen, C. J., Kummerlowe, M. N., Redmond, K. J., Rigamonti, D., Lim, M. K., & Kleinberg, L. R. (2016). Stereotactic radiosurgery: treatment of brain metastasis without interruption of systemic therapy. International Journal of Radiation Oncology, Biology, Physics, 95(2), 735–742. https://doi.org/10.1016/j.ijrobp.2016.01.054 .
doi: 10.1016/j.ijrobp.2016.01.054
pubmed: 27034175
Stera, S., Balermpas, P., Blanck, O., Wolff, R., Wurster, S., Baumann, R., Szücs, M., Loutfi-Krauss, B., Wilhelm, M. L., Seifert, V., Rades, D., Rödel, C., Dunst, J., Hildebrandt, G., Arnold, A., Meissner, M., & Kähler, K. C. (2019). Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research, 29(2), 187–195. https://doi.org/10.1097/CMR.0000000000000542 .
doi: 10.1097/CMR.0000000000000542
pubmed: 30802230
Kroeze, S. G. C., Fritz, C., Hoyer, M., Lo, S. S., Ricardi, U., Sahgal, A., Stahel, R., Stupp, R., & Guckenberger, M. (2017). Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treatment Reviews, 53, 25–37. https://doi.org/10.1016/j.ctrv.2016.11.013 .
doi: 10.1016/j.ctrv.2016.11.013
pubmed: 28056412
Sneed, P. K., Mendez, J., Vemer-van den Hoek, J. G. M., Seymour, Z. A., Ma, L., Molinaro, A. M., Fogh, S. E., Nakamura, J. L., & McDermott, M. W. (2015). Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Journal of Neurosurgery, 123(2), 373–386. https://doi.org/10.3171/2014.10.JNS141610 .
doi: 10.3171/2014.10.JNS141610
pubmed: 25978710